How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?

Area of Science:

• Oncology
• Hematology
• Clinical Medicine

Background:

• Hodgkin lymphoma (HL) exhibits high cure rates, yet treatment-related comorbidities pose significant risks to survivors.
• Therapeutic interventions, while effective, can lead to long-term health issues impacting quality of life.

Purpose of the Study:

• To review and analyze comorbidities in Hodgkin lymphoma survivors.
• To evaluate survivorship issues including fertility, secondary cancers, and quality of life.
• To explore optimal strategies for relapse detection and management.

Main Methods:

• Comprehensive literature review of studies on Hodgkin lymphoma treatment and survivorship.
• Analysis of data regarding long-term toxicities and comorbidities.
• Assessment of current and emerging therapeutic strategies, including checkpoint inhibitors.

Main Results:

• Survivors face risks of cardiovascular toxicity, secondary malignancies, and impaired fertility.
• The treatment paradigm is shifting towards minimizing toxicity while maintaining high cure rates.
• Novel therapies like checkpoint inhibitors show promise but require long-term toxicity assessment.

Conclusions:

• Hodgkin lymphoma survivors necessitate individualized, multidisciplinary follow-up care.
• Early detection and management of long-term treatment side effects are crucial for improving survivorship.
• Ongoing research is needed to fully understand the long-term impact of new therapies.